Exploring the Novel Therapeutic Potential of N-acetylcysteine in Depression,Bipolar Disorders and Anxiety

Abstract

Background

Anxiety disorders, bipolar disorder, and depression are prevalent mental health issues that have a substantial impact on both individuals and the community. Many people continue to have symptoms and do not get the right kind of relief from their existing drugs, even after trying conventional therapy methods. Therefore, to enhance the current treatment modalities and patient results, new therapeutic alternatives are required. In recent years, there has been an increase in interest in N-acetylcysteine (NAC) because of its many biological benefits, including its ability to modulate glutamate levels and its antioxidant and anti-inflammatory properties. According to studies, NAC has encouraging anti-depressant properties and may help treat bipolar disease by stabilizing mood and reducing the risk of relapses. Furthermore, through lowering oxidative stress and modifying neurotransmitter networks, NAC has been shown to lessen the symptoms of anxiety. The preclinical and clinical research examining the efficacy of NAC in depression, bipolar disorders, and anxiety are thoroughly analyzed in this review.

Methodology

Conclusion

NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. Performing a thorough clinical study will facilitate proper understanding its efficacy, safety and mechanisms of action.

Keywords

Anxiety disorders bipolar disorder depression N-acetylcysteine novel therapeutics

Introduction

N-acetylcysteine (NAC) is a sulfhydryl-containing drug that was first prescribed for medicinal purposes in 1967. It was initially patented in 1960.¹ Since 1969, NAC has been utilized clinically in cystic fibrosis,² and its application has grown to encompass chronic obstructive pulmonary disease and acetaminophen overdose; its clinical significance continues to grow. The World Health Organization (WHO) and the Food and Drug Administration (FDA) have both designated NAC as an essential medication.³ NAC is typically sold as an over-the-counter nutritional supplement with antioxidant qualities in several countries, including the USA, Canada, and Australia.⁴ Clinical applications of NAC have grown in tandem with our growing understanding of its activity. Apart from its well-established medicinal applications, there has been a surge in interest lately in the application of NAC in the management of neuropsychiatric disorders such as anxiety, depression, and bipolar disorder.⁵

NAC is a possible adjunctive treatment option for people with psychiatric disorders since it is a precursor to the antioxidant glutathione and has been demonstrated to control glutamate levels, reduce inflammation, and improve overall brain function.⁶ The use of NAC in psychiatric diseases has been the subject of numerous research, which has highlighted both its neuroprotective and neurotrophic qualities. The potential effectiveness of NAC in treating diseases such as bipolar disorder, schizophrenia, OCD, drug use disorders, and generalized anxiety disorder has been studied.² Studies have demonstrated that NAC supplementation may benefit people with psychiatric disorders by lowering symptoms, enhancing cognitive function, and improving treatment outcomes.⁷ The NAC complex and its multiple mechanisms of action in psychiatric diseases include antioxidant effects, modulation of inflammation, improvement of neuroplasticity, and regulation of glutamate neurotransmission.⁸ NAC is a viable option for the treatment of several psychiatric conditions due to its diverse neuroprotective qualities.

Millions of individuals worldwide suffer from depression, and while many are helped by modern anti-depressants, a sizeable fraction either do not get better or have unbearable side effects. NAC possesses anti-inflammatory and antioxidant qualities, which have demonstrated potential therapeutic benefits in treating depression.⁹ Another difficult psychiatric illness that needs appropriate long-term therapy is bipolar disorder. Mood stabilizers are frequently used to treat repeated manic and depressive episodes that bipolar disorder sufferers experience. These medications may not always work well and may have negative consequences. As an additional or alternative treatment for bipolar disorder, NAC has demonstrated promise. This may lessen the intensity and occurrence of manic and depressive episodes by regulating glutamatergic circuits that are dysregulated in the illness.¹⁰ Among the most prevalent mental health issues globally are anxiety disorders, for which benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) may not be the best or most appropriate treatments for some individuals. Anxiolytic effects of NAC have been demonstrated in preclinical and clinical investigations. It could function by lowering oxidative stress and modifying glutamatergic neurotransmission.¹¹ This review article aims to provide a comprehensive overview of the current evidence supporting the use of NAC in the management of depression, bipolar disorder, and anxiety, including recent clinical studies evaluating its effectiveness and safety in patients with these conditions. By synthesizing and critically evaluating the existing literature, this review seeks to shed light on the potential therapeutic applications of NAC in addressing the unmet needs of individuals suffering from mood and anxiety disorders.

Methodology

Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. Using the key terms “NAC,” “N-acetyl-l-cysteine,” “psychiatric disorders,” “anxiety,” “depression,” “bipolar disorder,” and other terms unique to each disorder, literature searches were conducted. A review of articles released in the past 20 years (until December 2022) was conducted, focusing on human research with a preference for meta-analyses or randomized control trials (RCTs). When available, preclinical or animal research was also included.

Mechanism of Action

NAC is a thiol that functions as an acetylated precursor of the amino acid l-cysteine. By giving one or two electrons, it can function as a nucleotide or as a radical reducer.^{12, 13} Its molecular structure, which consists of an amino group (NH₂) connected to a functional sulfhydryl group (–SH) and acetyl group (–COCH₃), is what allows it to perform metabolic activities that include direct and indirect antioxidant and mucolytic effects (Figure 1).¹⁴ Because of its free thiol group’s capacity to react with reactive oxygen and nitrogen compounds (RONS), NAC has direct antioxidant action.¹⁵ Under experimental conditions, NAC rapidly reacts with the reduced and protonated form of nitric oxide (•NE), nitroxyl (HNO), hydroxyl radical (•OH), nitrogen dioxide (•NO₂), carbon trioxide ion (CO₃•−), and thiyl radical (RS•). Superoxide (O₂•−), hydrogen peroxide (H₂O₂), and peroxynitrite (ONOO−) radical anion reactions are comparatively slow.¹⁶

Figure 1.

Source: Aldini et al.28

There are questions regarding the significance of NAC’s direct antioxidant capacity against RONS under physiological conditions because of its generally lower reaction rate when compared to other enzymatic and non-enzymatic antioxidants and other substrates, especially when taking into account other factors such as its endogenous concentration and location (cellular or extracellular).¹⁶ NAC may, however, have direct antioxidant action against some oxygen species, such as NO₂ and hypohaloacids (HOX), depending on its relative content of other thiols.¹⁶ Experimental research indicates that NAC, like other thiols, can bind with its free thiol to active redox metal ions, including heavy metals such as lead (Pb²⁺) and mercury (Hg²⁺) and transition metals such as copper (Cu²⁺) and iron (Fe³⁺), forming complexes that the body can easily eliminate.¹³ There have been few clinical trials examining NAC’s chelating abilities, even though it can lower metal ion levels in toxicity.¹⁷ The potential of NAC as a chelating agent remains to be determined, as does the extent to which its effects as an indirect antioxidant stems from its ability to enhance the intracellular tripeptide (l-γ-glutamyl-l-cysteinyl glycine) that contains cysteines called GSH (glutathione).¹⁸

The most prevalent non-protein thiol in the body, GSH is one of the most significant antioxidants that keep cells in their proper redox state. Apart from directly reacting with reactive chemicals, GSH also serves as a cofactor or substrate for other antioxidants.¹⁶ Because cysteine has a lower intracellular concentration, it acts as a rate-limiting factor for the manufacture of GSH. This characteristic clarifies NAC’s function as a prodrug of intracellular GSH and cysteine.¹⁹ Because NAC can raise intracellular cysteine levels, which raises GSH levels, it is significant as a potent antioxidant.¹⁹

As a result, NAC is one of the most essential drugs to prevent oxidative stress–induced damage in diseases linked with xenobiotic poisoning, such as paracetamol or GSH insufficiency.¹³ Furthermore, NAC can break down thiol proteins, including cysteinylated extracellular proteins, which release free thiols, which are more potent antioxidants and improve the synthesis of GSH. NAC’s reducing capacity is connected to another process that contributes to its indirect antioxidant activity. Low molecular weight (LMW) thiol ubiquitous groups and decreased protein sulfhydryl groups implicated in redox state modulation can be restored by NAC.²⁰ The ability of NAC to alter protein structure and/or function has also been reported in experimental studies.²¹ This includes changes in the tumor necrosis factor (TNF-α) receptor’s affinity for cytokines, reduction of angiotensin II receptor binding in vascular smooth muscle cells, and reduction of transforming growth factor beta 1 (TGF-β1) upon binding to beta-glucan of the transforming growth factor receptor type III (TβRIII).^{22, 23} Lastly, NAC also reduces inflammation by blocking nuclear factor kappa (NF-κB), the light chain enhancer of activated B-cells, which is essential for the inflammatory cascade and the immunological response linked to the oxidative response. NAC suppresses nuclear activation and translocation of NF-κB, a transcription factor that controls the expression of genes that promote inflammation.²⁴ It has been demonstrated that NAC prevents lipopolysaccharide-activated macrophages from releasing the inflammatory cytokines TNF-α, interleukin (IL)-1β, and IL-6.²⁵

Potential Mechanism of N-acetylcysteine in Psychiatric Disorders

NAC has a complex mode of action that includes anti-inflammatory effects, oxidative stress reduction, and glutamate modulation. These outcomes add to the medication’s therapeutic advantages in treating a range of psychiatric illnesses. The following are some important pathways via which NAC works in mental illnesses:

Modulation of glutamatergic neurotransmission: Glutathione is a powerful antioxidant that is essential for preserving redox balance and shielding neurons from oxidative damage. NAC functions as a precursor to glutathione.⁶ NAC can influence glutamatergic neurotransmission by elevating glutathione levels, namely, through controlling the cystine/glutamate antiporter system (xC−) and reestablishing the equilibrium between extracellular glutamate and cystine levels in the brain. This may lessen the neuroinflammation and excitotoxicity linked to mental illnesses.⁶

Anti-inflammatory effects: NAC possesses anti-inflammatory qualities that may aid in the reduction of neuroinflammation associated with mental illnesses. It prevents pro-inflammatory cytokines including IL-1β and TNF-α from being produced as well as the activation of NF-κB.⁶

Redox regulation: NAC reduces oxidative stress and shields neuronal cells from harm by acting as a scavenger of reactive oxygen species (ROS) and reactive nitrogen species (RNS). In psychiatric diseases, NAC can enhance cellular resilience and prevent oxidative damage by boosting antioxidant defenses and replenishing glutathione levels.⁶

Neurotransmitter system modulation: It has been demonstrated that NAC alters the activity of several neurotransmitter systems, such as glutamate, serotonin, and dopamine. NAC can alter neuronal signaling pathways linked to psychiatric diseases as well as synaptic transmission by influencing neurotransmitter release and reuptake.²⁶

It has been established that NAC may be used as a therapy approach for mental illnesses such as bipolar disorder, anxiety, and depression. The method by which NAC modulates the symptoms of psychiatric diseases is explained by its influence on decreasing oxidative or inflammatory cytokines.²⁷ According to a review based on available data, disruptions in brain energy metabolism, mitochondrial functions, and redox balance linked to environmental and genetic factors are responsible for the genesis and progression of psychiatric disorders.²⁸ These disruptions are not only clinically linked to disease-specific symptoms but also alter an individual’s circadian rhythm and metabolic rate. Antioxidant activity, decreased cytokine activity, modulation of dopamine release, reversal of mitochondrial dysfunction, reduction of apoptosis and ferroptosis, anti-inflammatory effects, increased neurogenesis, and increased glutamate release are just a few of the numerous significant roles that NAC plays.²⁹

Its antioxidant impact, which is mediated through multiple mechanisms, is arguably the most significant of them in the treatment of psychiatric diseases. By promoting glutathione synthesis, elevating glutathione S-transferase activity, scavenging free radicals, and activating group II metabotropic glutamate receptors to decrease glutamate turnover, NAC functions as an antioxidant.³⁰ The primary endogenous antioxidant in the brain is glutathione. Glutathione in the brain is increased when l-cysteine levels are raised with NAC administration, as this compound’s rate of formation is dependent on l-cysteine availability.¹⁶ Antioxidants lessen oxidative stress, which has a role in the etiology of numerous mental illnesses.¹⁸

An imbalance between tissue redox defense and ROS, including superoxide, peroxynitrite, and hydrogen peroxide, is known as oxidative stress. Increased ROS, compromised antioxidant defenses, or unrepaired oxidative damage could be the cause.³¹ ROS induce DNA changes, peroxidation of cellular lipids, and inactivation of significant respiratory chain enzymes.³¹ Superoxide dismutase, glutathione reductase, and peroxidase are examples of antioxidant enzymes that convert ROS into less harmful molecules and shield the brain from oxidative stress–related damage.³¹ By boosting the production and storage of glutathione disulfide, which results in export and extracellular hydrolysis, protein S-glutathionylation, and the development of glutathione-dependent humans, severe long-term oxidative stress can cause glutathione depletion.³² It has been demonstrated that NAC can prevent mitochondrial malfunction, which is linked to oxidative stress.³³

Role of N-acetylcysteine in Psychiatric Diseases

Depression

Unipolar depression is linked to multiple oxidative disruptions, such as oxidative harm in red blood cells, elevated antioxidant enzyme levels (primarily superoxide dismutase) in peripheral tissues that are decreased by anti-depressant therapy, and bio-oxidative stress in the frontal cortex of depressed individuals’ brains during coping.³⁴ It is believed that NAC’s ability to reduce oxidative stress by raising glutathione levels contributes to its anti-depressant effects.³⁵ Because of its anti-inflammatory qualities and elevated extracellular glutamate levels, NAC may also have depressive effects.³⁶ Treatment-resistant depression may benefit greatly from NAC’s anti-inflammatory properties.³⁷

In one animal study, it was observed that NAC shortens rats’ periods of immobility during forced swimming tests in animal experiments.³⁵ Chronic administration of NAC produced effects akin to imipramine in male Wistar rats that had their bulbs removed, a paradigm used to study depression.³⁸ Results from clinical investigations have been inconsistent. NAC (2,000 mg/day) demonstrated indications of larger effects for more severe depression (MADRS scores > 24) in a large RCT with 269 participants, finding a modest but substantial improvement in MADRS scores at 16 weeks of follow-up (the intervention terminated at 12 weeks) compared to placebo.³⁹ Additionally, the study discovered a more efficient longitudinal interview and notable advancements in the Longitudinal Interval Follow-up Assessment of Impaired Functioning Range Tool (VIVO-RIFT) and Longitudinal Interval Monitor-up Assessment (SLICE)-LIFE.³⁹

Higher levels of glutamate-glutamine and N-acetylaspartate and lower levels of myoinositol were predictive of whether a patient was in the NAC therapy group, according to the MR spectroscopy of a subset of the research.⁶ Reduced oxidative stress was predicted by higher glutamate-glutamine and N-acetyl aspartate levels.⁴⁰ The impact of NAC on enhancing anti-depressant medication in patients with treatment-resistant depression is presently being examined in a sizable RCT.³⁷ NAC was found to significantly enhance function in a meta-analysis of seven RCTs that looked at NAC as an additional treatment for unipolar depression. On the Clinical Global Impression Severity Scale, this was discovered to be a substantial norm (CGI-S) not on other performance measures (such as the LIFE-RIFT, SLICE-LIFE, and Social and Vocational Functioning Assessment Scale (SOFAS)) when contrasted with a placebo.⁴⁰ To sum up, one RCT looked just at NAC in cases of unipolar depression and found a small but noteworthy outcome. Furthermore, more thorough and productive research is required before it may be suggested for therapeutic usage.

Bipolar Disorder

The body of research on bipolar disorder (BD) points to mitochondrial dysfunction as a potential pathophysiological factor. Therefore, treatments that impact mitochondrial activity might help BD patients clinically manage their depression symptoms. In individuals with BD and depressive symptoms, a randomized, placebo-controlled clinical trial with 181 participants was unable to show the benefits of 2,000 mg/day NAC supplementation either alone or in conjunction with other antioxidants.⁴¹ NAC (2 g day 1; 24 weeks; n = 75) was administered as an adjunct to the usual medication in a 24-week double-blind, multicenter, randomized controlled trial of patients with BD in the maintenance phase. The trial had a four-week washout period and found that NAC improved the majority of secondary scales and depressive symptoms.⁴²

During the randomized controlled experiment, participants with BD (n = 24) were assigned to receive aspirin (1 g day 1), a combination of aspirin and NAC (1 g each), or a placebo.⁴³ Following an initial eight-week therapy phase, patients receiving a placebo and those receiving NAC in addition to aspirin showed a roughly 70% chance of receiving a good treatment response. NAC and aspirin combined therapy produced a higher chance of a treatment response (67%) after a 16-week treatment period compared to placebo (55%), NAC (57%), and aspirin (33%). IL-6 and CRP levels were unaffected at either 8 or 16 weeks.⁴³

When NAC was given orally at 1,000 mg/day to a small sample of patients (14 subjects), Magalhães et al. exhibited interesting findings, with the treated group’s manic and depressive symptoms of BD II completely resolved.⁴⁴ Furthermore, NAC was assessed as an adjunctive treatment for BD and MDD by Kishi et al., who carried out a systematic review with a meta-analysis of clinical, randomized, and double-blind trials.⁴⁵ They found that while NAC was able to lower the Global Clinical Impression Severity Score Scale, no discernible improvement in symptoms was seen. The clinical effectiveness of NAC supplementation in MDD patients is being studied, as well as any possible impact it may have on oxidative stress and inflammation (IDClinicalTrials.gov NCT02972398).

Anxiety Disorder

Neuroinflammation, glutamatergic hyperactivity, and oxidative stress are linked to anxiety disorders.⁴⁶ It is unknown if NAC’s glutamate, antioxidant, or antioxidant-modifying qualities are what cause its anxiolytic effects. Greater oxidative stress and anxiety-like behavior were found to be connected with greater microglial activation, which includes phagocytosis, inflammation, disruption of the blood–brain barrier, and increased synthesis of 2-OH-estradiol, according to a preclinical investigation done on mice.⁴⁶ In rat offspring from an experimental model of autism induced by valproate, a 10-day NAC (150 mg/kg; i.p.) treatment reversed the duration and frequency of social interaction deficits and anxiety-like behaviors. These effects were blocked by the administration of the mGlu2/3 receptor antagonist LY341495 into the amygdala, indicating the involvement of a glutamate-related mechanism.⁴⁷

Sprague-Dawley rats treated with NAC (100 mg/kg; i.p.) and morphine for 14 days showed improvements and a decrease in anxiety-like behaviors. This resulted from changes in oxidative stress markers that were anxiogenic in nature, specifically a drop in malondialdehyde (MDA) levels and a rise in GSH and nitrite/nitrate levels in the hippocampal regions.⁴⁸ The anxiety-like behaviors associated with nicotine-induced withdrawal in mice were evaluated 18–24 hours after continuous drug administration, and a single dose of NAC (15, 30, or 120 mg/kg; i.p.) did not affect them.⁴⁹ After consuming alcohol, rats received four days of NAC treatment (60 and 90 mg/kg; i.p.) to reduce anxiety caused by alcohol withdrawal. This prevented the decrease in peripheral and total crossings, rearing, and total activity in the open field test, as well as the increases in leptin (90 mg/kg) and corticosterone levels (both doses) that resulted from alcohol withdrawal.⁵⁰ In the open field, light/dark, hole table, social interaction, stress-induced hyperthermia models in mice, and the light/dark test in zebrafish, NAC decreased anxiety-like behavior.⁵¹ The behavioral and physiological effects of 14 days of chronic stress were reversed in zebrafish after seven days of NAC therapy.⁵¹

Cisplatin, which is frequently used in cancer, has neurotoxic anxiolytic effects that are mediated by elevated oxidative stress.⁵² NAC supplementation of cisplatin decreased oxidative stress and cisplatin-induced apoptosis in the hippocampus.⁵² NAC did not, however, lower assessed oxidative stress from peripheral sources in an RCT involving 57 patients (28 in the NAC group and 29 in the placebo group) receiving cisplatin augmentation for head and neck cancer.⁵³ It is important to acknowledge that, in contrast to other studies that have demonstrated favorable outcomes, the NAC dose and treatment duration in this research were modest, and anxiety was not measured as an end point. The results of the study indicate that NAC did not reduce the antitumor efficaciousness of cisplatin, indicating the safety of further cancer research.⁵³ A case study describing the addition of NAC (2,400 mg/day) to sertraline in the treatment of a 17-year-old male patient with social anxiety disorder and generalized anxiety disorder has been reported.⁵⁴ The patient’s CGI-S score decreased from five to two in just eight weeks. In conclusion, no controlled studies have looked into the use of NAC in the treatment of anxiety disorders, despite some preclinical evidence and theoretical explanations for its possible application.

Safety Profile and Adverse Effects

Excellent safety characteristics characterize NAC. Up to 10 × 2,800 mg of oral medication was tested for safety in a clinical trial, and no serious adverse effects were noted.⁵⁵ NAC is an oral medication that is well tolerated and does not have any serious side effects, according to all large systematic reviews.⁵⁶ The most frequent adverse effects documented in clinical trials using NAC were digestive, including nausea, vomiting, diarrhea, bloating, cramps, minor stomach discomfort, and heartburn.⁵⁷ Aside from these general adverse effects, other people have suffered headaches, rashes, elevated blood pressure, dry mouth, exhaustion, muscular soreness, insomnia, runny nose, nasal congestion, restlessness, and dizziness. Nevertheless, these are anecdotal instances, and there have been no reliable reports of major side effects from NAC therapy.⁵⁷ As an adjuvant therapy, NAC has been shown to guard against the negative effects of mental drugs.⁵⁸ Glutathione, anticancer medications, and paracetamol may interact with NAC. It also amplifies the effects of comparable medications, such as nitrate vasodilators, increasing the risk of hypotension.⁵⁷ NAC should therefore be used cautiously in individuals who are taking these drugs.

Discussion

NAC has demonstrated encouraging therapeutic benefits in a range of psychiatric disorders by reducing oxidative stress, exhibiting anti-inflammatory properties, modulating glutamatergic neurotransmission, and modifying neurotransmitter systems, all of which help to alleviate symptoms and neuropathologies.⁶ According to research, NAC helps lessen symptoms of anxiety, bipolar disorder, depression, obsessive-compulsive disorder, schizophrenia, and drug use disorders.²⁶ Additionally, it has been demonstrated to improve cognitive performance in patients with certain psychiatric diseases and increase the efficacy of traditional treatments.⁵⁹

When treating psychiatric diseases, the recommended daily amount of NAC is usually divided into two or three doses, ranging from 1,200 to 3,600 mg. Depending on an individual’s response and the severity of the symptoms, higher doses can be required in some situations.⁶ Preclinical and clinical research on depression, anxiety, and bipolar disorder have demonstrated the behavioral efficacy of NAC. It has been demonstrated to lessen obsessive behaviors, elevate mood, and lessen anxiety.⁶⁰

The effectiveness of NAC as an adjuvant treatment for patients with major depressive illness was examined in a 2019 study by Berk et al. The findings demonstrated that these individuals’ overall functioning and depressive symptoms were both improved by NAC supplementation.⁶¹ Supplementing with NAC reduced anxiety symptoms in patients with generalized anxiety disorder, according to a randomized controlled experiment conducted by Sarris et al. According to the study, those taking NAC experienced much lower levels of stress and anxiety than the placebo group.⁶²

Overall, these recent clinical studies demonstrate the potential effectiveness of NAC as an adjunctive treatment in patients with depression, anxiety, and bipolar disorders. Further research is needed to confirm these findings and elucidate the underlying mechanisms of action of NAC in these psychiatric conditions. Based on recent studies, there is strong evidence that NAC is a novel and successful treatment for anxiety, bipolar disorder, and depression. More research is required because many of the RCTs and preclinical studies that have been discussed have provided only basic information about the efficacy of NAC in therapy. On the other hand, NAC seems to be a promising therapeutic target and provides a therapeutic option in a field where other treatments are inadequate or ineffective. Evidence points to NAC’s potential anti-depressant benefits, which may stem from its anti-inflammatory and antioxidant qualities as well as how it affects glutamate and dopamine neurotransmission.⁹ Because of its capacity to control glutamatergic pathways and possibly lessen the severity and frequency of manic and depressive episodes, NAC is a viable alternative or complementary treatment for bipolar illness.¹⁰ Furthermore, NAC has demonstrated anxiolytic benefits, potentially through lowering oxidative stress and modifying glutamatergic neurotransmission.¹¹ Even if the data is encouraging, more extensive and well-designed research is still required to fully understand the clinical effectiveness of NAC in these conditions. It is noteworthy that a lot of recent research exclusively examines NAC as an adjuvant treatment. NAC monotherapy clinical trials are necessary to accurately ascertain the drug’s therapeutic potential. While oxidative stress appears to be a fairly non-specific finding in several psychopathologies, glutamate dysregulation and inflammatory pathways have also been widely reported.¹¹

NAC’s apparent lack of specificity in early studies is intriguing and suggests that it may target pathways common to different diseases. It is possible that some places are more beneficial than others as the body of evidence grows. Because glutamate, the most widely distributed neurotransmitter, interacts with other neurotransmitters, such as serotonin and dopamine, people suffering from diseases such as bipolar disorder and depression may benefit from indirect manipulation of these pathways through modifications in glutamatergic activity.¹² Since oxidative stress is altered in the majority of these conditions, there may be a common link to therapy efficacy. In a similar vein, the advantages from NAC administration might be attributed to the regulation of inflammatory pathways. Most research has focused on the connection between inflammation and depression.⁶³ Further research is necessary to determine the ideal dosage and long-term safety profile of NAC. Furthermore, the precise dosage of NAC is yet to be established. Studies on dose finding may demonstrate the same efficacy at lower doses or increased efficacy at higher levels. Research is necessary, nonetheless, considering the great safety profile of NAC and the possible advantages demonstrated in a number of clinical trials and uncontrolled studies. NAC is used to treat anxiety, bipolar illness, and depression.⁵⁷ This improbable therapeutic instrument presents novel pathways as potential targets for therapy. This opens the door for the creation of additional logical, hypothesis-driven therapies. NAC’s apparent safety, tolerability, affordability, and accessibility all contribute to its allure.

Conclusion

The potential therapeutic uses of NAC in the field of psychiatry are highlighted in this review study. An affordable and easily accessible substance, NAC has demonstrated encouraging effects in treating a number of mental illnesses, such as anxiety, bipolar disorder, and depression. To enhance patient outcomes, however, more funds and resources for research should be invested in examining NAC in larger clinical trials. This will give clinicians access to evidence-based therapy alternatives. To sum up, NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. We can improve our understanding of the efficacy and safety of this medication by performing thorough clinical studies and broadening our understanding of its mechanisms of action. This will ultimately lead to better management and treatment of patients with psychiatric disorders.

Abbreviations

NAC: N-acetylcysteine; FDA: Food and Drug Administration; WHO: World Health Organization; RCT: Randomized controlled trial; GSH: Glutathione; TNF-α: Tumor necrosis factor-alpha; TGF-β1: Transforming growth factor beta 1; TβRIII: Transforming growth factor receptor betaglycan; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; MADRS: Montgomery–Åsberg Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation-Range of Impaired Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation; CGI-S: Clinical Global Impression Scales-Severity; SOFAS: Social and Occupational Functioning Assessment Scale; BD: Bipolar disorder; MDD: Major depressive disorders

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Lillibridge

, Docter

and Eidelman

“Oral administration of n-acetyl cysteine in the prophylaxis of “meconium ileus equivalent”. J Pediatr 1967; 71(6): 887–889. DOI: 10.1016/s0022-3476(67)80019-2

Gracey

, Burke

and Anderson

C M.

Treatment of abdominal pain in cystic fibrosis by oral administration of n-acetyl cysteine. Arch Dis Child 1969; 44: 404–405.

Tardiolo

, Bramanti

and Mazzon

Overview on the effects of n-acetylcysteine in neurodegenerative diseases. Molecules 2018; 23: 3305. DOI: 10.3390/molecules23123305

Mokhtari

, Afsharian

, Shahhoseini

, . A review on various uses of N-acetyl cysteine. Cell J 2017; 19: 11–17. DOI: 10.22074/cellj.2016.4872

Kessler

, Berglund

, Demler

, . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication. JAMA 2003; 289: 3095–3105. DOI: 10.1001/jama.289.23.3095

Berk

, Malhi

, Gray

, . The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34(3): 167–177.

Afshar

, Solhani

, Kiani

, . N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012; 32(6): 797–803.

McClure

, Gipson

, Malcolm

, . Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 2014; 28(2): 95–106.

Cassano

, Rucci

, Frank

, . The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 2004, 161: 1264–1269. DOI: 10.1176/appi.ajp.161.7.1264

10.

Sartori

, Singewald

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019: 107402. DOI: 10.1016/j.pharmthera.2019.107402

11.

Pfaff

, Beltz

, King

, . Medicinal thiols: current status and new perspectives. Mini Rev Med Chem 2020; 20: 513–529. DOI: 10.2174/13895575196661911

12.

Samuni

, Goldstein

, Dean

, . The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830: 4117–4129. DOI: 10.1016/j.bbagen.2013.04.016

13.

Radomska-Lesnniewska

M and Skopinski P. N-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications. Centr Eur J Immunol 2012; 37: 57–66. DOI: 10.3390/antiox10060967

14.

Pei

, Liu

, Yang

, . Biological activities and potential oral applications of N-acetylcysteine: progress and prospects. Oxid Med Cell Longev 2018: 22–2018. DOI: 10.1155/2018/2835787

15.

Dodd

, Dean

, Copolov

, . N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8: 1955–1962. DOI: 10.1517/14728220802517901

16.

Dringen

and Hirrlinger

Glutathione pathways in the brain. Biol Chem 2003; 384: 505–516. DOI: 10.1515/BC.2003.059.

17.

Rushworth

, Megson

IL.

Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 2014; 141: 150–159. DOI: 10.1016/j.pharmthera.2013.09.006

18.

Shahripour

, Harrigan

(Alexandrov AV. N-acetylcysteine NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 2014, 4: 108–122. DOI: 10.1002/brb3.208

19.

Ezerina

, Takano

, Hanaoka

, . N-Acetyl cysteine functions as a fast-acting antioxidant by triggering intracellular h2s and sulfane sulfur production. Cell Chem Biol 2018; 25: 447–459. DOI: 10.1016/j.chembiol.2018.01.011

20.

Ullian

, Gelasco

, Fitzgibbon

, . N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells. J Am Soc Nephrol 2005; 16: 2346–2353. DOI: 10.1681/ASN.2004060458

21.

Drexhage

, Knijff

, Padmos

, . The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010; 10: 59–76. DOI: 10.1586/ern.09.144

22.

Meurer

, Lahme

, Tihaa

, . N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps: the biochemical and biological efficacy of a multifunctional, antifibrotic drug. Biochem Pharmacol 2005; 70: 1026–1034. DOI: 10.1016/j.bcp.2005.07.001

23.

De Andrade

, Moura

, Dos Santos

, . Oxidative stress and inflammation in hepatic diseases: therapeutic possibilities of N-acetylcysteine. Int J Mol Sci 2015; 16: 30269–30308. DOI: 10.3390/ijms161226225

24.

Palacio

, Markert

, Martínez

Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm. Res 2011; 60: 695–704. DOI: 10.1007/s00011-011-0323-8

25.

Dinan

TG.

Inflammatory markers in depression. Curr Opin Psychiatry 2009; 22: 32–36. DOI: 10.1097/YCO.0b013e328315a56122

26.

Dean

Giorlando F and Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential 10 of 12 mechanisms of action. J Psychiatry Neurosci 2011; 36: 78–86. DOI: 10.1503/jpn.100057

27.

Tardiolo

Bramanti P and Mazzon E. Overview on the effects of n-acetylcysteine in neurodegenerative diseases. Molecules 2018; 23: 3305. DOI: 10.3390/molecules23123305

28.

Aldini

, Altomare

, Baron

, . N Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res ; 52: 751–762. DOI: 10.1080/10715762.2018.1468564

29.

Aruoma

, Halliwell

, Hoey

, . The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593–597.

30.

Holdiness

MR.

Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991; 20: 123–134. DOI: 10.2165/00003088-199120020-00004

31.

Borgstrom

, Kagedal

and Paulsen

Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986; 31: 217–222. DOI: 10.1007/BF00606662

32.

Raza

, John

and Shafarin

NAC attenuates LPS-induced toxicity in aspirin-sensitized mouse macrophages via suppression of oxidative stress and mitochondrial dysfunction. PLoS One 2014; 9: 103379. DOI: 10.1371/journal.pone.0103379

33.

Michel

, Frangou

, Thiemeyer

, . Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder—a postmortem study. Psychiatry Res 2007; 151: 145–150.

34.

Ferreira

, Biojone

, Joca

, . Anti-depressantlike effects of N-acetyl-L-cysteine in rats. Behav Pharmacol 2008; 19: 10–1097. DOI: 10.1097/FBP.0b013e3283123c98

35.

Porcu

, Urbano

, Jr

Verri WA

, . Effects of adjunctive N-acetylcysteine on depressive symptoms: modulation by baseline high-sensitivity C-reactive protein. Psychiatry Res 2018; 263: 268–274. DOI: 10.1016/j.psychres.2018.02.056

36.

Yang

, Bosker

, Li

, . N-acetylcysteine as add-on to anti-depressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-con. BMC Psychiatry . DOI: 10.1186/s12888-018-1845-1

37.

Smaga

, Pomierny

, Krzyżanowska

, . N-acetylcysteine possesses anti-depressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Progr Neuro Psychopharmacol Biol Psychiatry 2012; 39: 280–287.

38.

Berk

, Dean

, Cotton

, . The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 2. DOI: 10.4088/JCP.13m08454

39.

Dean

, van den Buuse

, Bush

, . A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009; 16: 2965–2976. DOI: 10.2174/092986709788803060

40.

Yang

, Bosker

, Li

41.

Berk

, Copolov

, Dean

, . N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008 Sep 15; 64(6): 468–475. DOI: 10.1016/j.biopsych.2008.04.022

42.

Deepmala

, Slattery

, Kumar

, . Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 2015; 55: 294–321.

43.

Bauer

, Green

, Colpo

, . A double-blind, randomized, placebo controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry ; 80(1): 18m12200. DOI: 10.4088/JCP.18m12200

44.

Magalhães

, Dean

, Bush

, . N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo controlled trial. J Affect Disord 2011; 129: 317–320. DOI: 10.1016/j.jad.2010.08.001

45.

Kishi

, Miyake

, Okuya

, . N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology 2020; 237: 3481–3487. DOI: 10.1111/bdi.13039

46.

Santos

, Herrmann

, Elisabetsky

, . Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review. Braz J . DOI: 10.1590/1516-4446-2018-0005

47.

Chen

, Lin

, Ng

, . Activation of mGluR2/3 underlies the effects of N acetylcysteine on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism. Front Behav Neurosci ; 8: 219. DOI: 10.3389/fnbeh.2014.00219

48.

Famita Freshi

and Karimian

Reduction of anxiety level is associated with an oxidative-stress imbalance in the hippocampus in morphine administration period in male rats. J Addict Dis 2020; 38(1): 64–70. DOI: 10.1080/10550887.2020.1717281

49.

Bowers

, Jackson

, Maldoon

, . N-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice. Psychopharmacology; 233(6): 995–1003. DOI: 10.1007/s00213-015-4179-4

50.

Schneider R

, Santos

, Clarimundo

, . N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol ; 49(3): 259–263. DOI: 10.1016/j.alcohol.2015.01.009

51.

Mocelin

, Marcon

, D’ambros

, . N-Acetylcysteine reverses anxiety and oxidative damage induced by unpredictable chronic stress in zebrafish. Mol Neurobiol 2019; 56: 1188–1195. DOI: 10.1007/s12035-018-1165-y

52.

Stankovic

JSK

, Selakovic

, Mihailovic

, . Antioxidant supplementation in the treatment of neurotoxicity induced by platinum-based chemotherapeutics—a review. Int J Mol Sci 2020; 21: 7753. DOI: 10.3390/ijms21207753

53.

Visacri

, Quintanilha

, de Sousa

, . Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo controlled trial involving patients with head and neck cancer. Cancer Med 2019; 8: 2020–2030. DOI: 10.1002/cam4.2072

54.

Strawn

, Saldaña

SN.

Treatment with adjunctive N-acetylcysteine in an adolescent with selective 11 of 12 serotonin reuptake inhibitor-resistant anxiety. J Child Adolesc Psychopharmacol . DOI: 10.1089/cap.2012.0066

55.

Miller

, Rumack

BH.

Clinical safety of high oral doses of acetylcysteine. Semin Oncol 1983; 10: 0093–7754. DOI: 10.1155/2018/2469486

56.

LaRowe

, Mardikian

, Malcolm

, . Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006; 15: 105–110.

57.

Minarini

, Ferrari

, Galletti

N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol ; 3: 279–292. DOI 10.1080/17425255.2017.1251580

58.

Farokhnia

, Azarkolah

and Adinehfar

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Clin Neuropharmacol ; 36(6): 185–192. DOI: 10.1097/WNF.0000000000000001

59.

Fernandes

, Berk

N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. CNS Drugs 2014; 28(10): 975–986.

60.

Grant

, Odlaug

, Kim

SW.

N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2011; 68(5): 527–533.

61.

Berk

, Woods

, Nelson

, . Effect of N-acetyl cysteine on depressive symptoms in the 2-year follow-up of the randomized controlled Hordaland health study. J Affect Disord 2019; 265: 63–69.

62.

Sarris

, Singh

, Thomas

, . The adjunctive use of N-acetylcysteine in anxiety disorders: a systematic review and meta-analysis. J Affect Disord 2020; 263: 51–58.

63.

Uraz

, Tahan

, Aytekin

, . N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats. Scand J Clin Lab Invest 2013; 73: 61–6. DOI: 10.3109/00365513.2012.734859